title: Efficacy of oral iodide therapy on neonatal hyperthyroidism caused by maternal Graves' disease.
abstract: OBJECTIVE
  To verify the efficacy of oral iodide therapy in treating a case of early neonatal hyperthyroidism due to maternal Graves' disease.
  
  
  METHODS
  We report a case of neonatal hyperthyroidism which occurred in a 2,650-gram, female baby, born at 39 weeks' gestational age (GA) to a 30-year-old mother affected by Graves' disease and treated with thionamides (propylthiouracil) from the 20th week of gestation. A fetal goiter, due to maternal therapy, had been observed by ultrasound scan at 31 and 35 weeks of gestation, with contemporary low cord thyroid hormone levels. Two intra-amniotic injections of levothyroxine were then performed at 34 and 36 weeks of gestation, which led to a significant reduction of fetal goiter and to normalization of cord thyroid hormone levels. The neonatal clinical course was characterized by symptoms of hyperthyroidism from the 2nd to 3rd days of life (irritability, tachycardia, tachypnea, hyperphagia), mostly during feeding. Oral treatment with potassium iodide (KI, 8 mg x 3 times a day) was started at 23 days of life.
  
  
  RESULTS
  Treatment with KI led to a significant reduction of neonatal clinical symptoms and to a normalization of hormone levels within 4 days of therapy. The treatment was discontinued in 13th week of life because of neonatal well-being and normal hormone levels.
  
  
  CONCLUSIONS
  We believe that KI therapy is effective in treating neonatal hyperthyroidism and does not cause suppression of neonatal thyroid activity, which is possible using antithyroid drugs like thionamides.
authors.affiliation: Institute of Pediatrics, Department of Neonatology, Catholic University of the Sacred Heart, Rome, Italy.
authors.forename: G
authors.initials: G
authors.lastname: Maragliano
authors.forename: A A
authors.initials: AA
authors.lastname: Zuppa
authors.forename: M G
authors.initials: MG
authors.lastname: Florio
authors.forename: M E
authors.initials: ME
authors.lastname: Scapillati
authors.forename: P
authors.initials: P
authors.lastname: Girlando
authors.forename: B
authors.initials: B
authors.lastname: Crescimbini
authors.forename: C
authors.initials: C
authors.lastname: Cafforio
authors.forename: G
authors.initials: G
authors.lastname: Noia
authors.forename: A F
authors.initials: AF
authors.lastname: Cavaliere
authors.forename: G
authors.initials: G
authors.lastname: Tortorolo
mesh_terms: D000650:Amnion; D005260:Female; D005315:Fetal Diseases / Q000139:chemically induced / Q000000981:diagnostic imaging; D006042:Goiter / Q000139:chemically induced / Q000000981:diagnostic imaging / Q000188:drug therapy; D006111:Graves Disease / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D006980:Hyperthyroidism / Q000188:drug therapy* / Q000209:etiology; D007231:Infant, Newborn; D011193:Potassium Iodide / Q000008:administration & dosage / Q000627:therapeutic use*; D011247:Pregnancy; D011248:Pregnancy Complications; D011441:Propylthiouracil / Q000009:adverse effects / Q000627:therapeutic use; D013974:Thyroxine / Q000008:administration & dosage / Q000627:therapeutic use; D016216:Ultrasonography, Prenatal
chemical_list: D011193:Potassium Iodide; D011441:Propylthiouracil; D013974:Thyroxine